Skip to main
BSX
BSX logo

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 43 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 16%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific has demonstrated strong financial performance, with total sales reaching $4.561 billion in the fourth quarter, reflecting a 19.5% year-over-year increase, significantly surpassing market projections. The company’s impressive growth is primarily driven by its Cardiovascular business, which achieved a remarkable 27% year-over-year growth and comprises 65% of fourth-quarter sales. With projected operating margin expansion and a strategic focus on reinvesting in research and development, Boston Scientific is well-positioned for continued success, especially benefiting from its highly leveraged operational structure for enhanced earnings per share growth amid stronger-than-expected revenue increases.

Bears say

The analysis of Boston Scientific reveals a negative outlook due to several fundamental factors impacting its financial performance. The company's gross margin declined year-over-year despite maintaining high operating margins, indicating pressure on profitability driven by capital sales limitations and competitive market dynamics. Furthermore, potential risks such as lower-than-expected sales in key product segments, competitive pressures from both established and emerging players, and broader market disruption from COVID-19 create significant uncertainty regarding sustained revenue growth and operating margin stability beyond the current fiscal year.

Boston Scientific (BSX) has been analyzed by 43 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 16% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 43 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.